<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A case of <z:chebi fb="5" ids="28304">heparin</z:chebi> resistance and its management during cardiopulmonary bypass is reported </plain></SENT>
<SENT sid="1" pm="."><plain>A patient with a history of post-<z:mpath ids='MPATH_124'>infarct</z:mpath> <z:mp ids='MP_0006112'>angina</z:mp> and <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> was treated with intravenous <z:chebi fb="5" ids="28304">heparin</z:chebi> infusion for five days prior to myocardial revascularisation surgery </plain></SENT>
<SENT sid="2" pm="."><plain>He required 13,500 IU/kg of <z:chebi fb="5" ids="28304">heparin</z:chebi> to increase his activated clotting time to a therapeutic level for safe institution of cardiopulmonary bypass </plain></SENT>
<SENT sid="3" pm="."><plain>This phenomenon of <z:chebi fb="5" ids="28304">heparin</z:chebi> resistance was postulated to be due to consumption of circulating antithrombin III as a result of prior heparinisation </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment with fresh frozen plasma restored <z:chebi fb="5" ids="28304">heparin</z:chebi> effectiveness </plain></SENT>
</text></document>